Focal segmental glomerulosclerosis

This study tested whether the drug Acthar can prevent focal segmental glomerulosclerosis (FSGS) from coming back in people who receive a kidney transplant. Fifteen adults with FSGS and advanced kidney disease took part. Researchers measured how many had FSGS return by looking at …

This phase 2 trial tested the drug obinutuzumab in 20 adults with a kidney disease called primary FSGS. The participants had not responded well to or could not take standard treatments like steroids. The goal was to see if obinutuzumab could reduce protein leakage in the urine, a…

This study tested whether baricitinib, a drug used for arthritis, can safely reduce high protein levels in the urine of African American adults with a specific genetic form of kidney disease (APOL1). Eight participants took the drug to see if it lowered their urine protein and pr…

This Phase 3 trial tested whether sparsentan, a drug that blocks two pathways involved in kidney damage, can better protect kidney function than the standard treatment irbesartan in people with focal segmental glomerulosclerosis (FSGS). The study enrolled 371 adults and children …

This study tested a new medicine, BI 764198, in 67 adults with a kidney disease called FSGS. Participants took different doses of the medicine or a placebo daily for 12 weeks. The goal was to see if the medicine could reduce protein in the urine, a sign of better kidney health. T…

This study tested an experimental drug called R3R01 in 43 people with two rare kidney diseases (Alport syndrome and focal segmental glomerulosclerosis) whose protein in urine remained high despite standard treatment. The main goals were to check safety and see if the drug could r…

This study tested a new drug called VX-147 in 16 adults with a specific genetic form of kidney disease (APOL1-mediated FSGS). The goal was to see if the drug could reduce protein in the urine, a sign of kidney damage, and to check its safety. The drug is taken by mouth and aims t…

This study tested whether giving the drug rituximab along with a blood-filtering procedure called plasmapheresis right before a kidney transplant could prevent focal segmental glomerulosclerosis (FSGS) from recurring. The trial enrolled 21 children and adults with FSGS who were g…

This study searched for genetic factors that may cause focal segmental glomerulosclerosis (FSGS), a kidney disease that can lead to kidney failure. Researchers compared DNA from 616 people, including African-Americans with FSGS, African-Americans with HIV but no FSGS, and non-Afr…

This completed study looked at why some people develop scarring in their kidneys, including rare diseases like FSGS and a mysterious form of chronic kidney disease affecting farm workers. Researchers collected blood, urine, and kidney tissue from 537 participants to better unders…

This study looks at immune cell patterns in people with three types of nephrotic syndrome—membranous nephropathy, minimal change disease, and focal segmental glomerulosclerosis. Researchers aim to see if certain immune cells can serve as biomarkers to track how well a patient res…

This study followed nearly 6,000 people with kidney disease from around the world. Researchers collected routine test results like kidney function and protein in urine to better understand how the disease progresses. The goal was to gather information, not to test a new treatment…